Clinical Trial Update: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ripretinib to sunitinib in adults with advanced gastrointestinal stromal tumor (GIST) harboring KIT exon mutations after imatinib. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Ripretinib (ripretinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: GIST | Phase 3 | Status: ACTIVE_NOT_RECRUITING